Literature DB >> 27493944

Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives.

Matthias F Häfner1, Jürgen Debus1.   

Abstract

BACKGROUND: Multimodal treatment approaches are indispensable for patients with advanced-stage colorectal cancer. Radiotherapy has been established as essential part of perioperative concepts and was introduced as an option to face challenges such as local relapse or oligometastases.
METHODS: A literature review was performed to summarize evidence and current standards of radiotherapeutic concepts in the treatment of colorectal cancer.
RESULTS: For stage II/III rectal cancer, neoadjuvant radiotherapy is superior to adjuvant treatment. Two preoperative regimens have been established and are commonly used with different objectives: short-course radiotherapy (SC-RT) and long-course chemoradiotherapy (LC-CRT). Both reduce the risk of local relapse. Additionally, LC-CRT aims at downsizing the tumor to potentially reduce radicalness of surgery. There is increasing evidence that not all stage II/III rectal cancer patients need neoadjuvant irradiation but also that in some cases surgery might be omitted. Stereotactic body radiotherapy (SBRT) of the liver shows high rates of local control in oligometastatic patients. Intraoperative and particle radiotherapy extend the spectrum of treatment options for locally recurrent patients.
CONCLUSION: Radiotherapeutic concepts are crucial for the primary management of locally advanced colorectal cancer and can essentially contribute to treatment approaches in locally recurrent, oligometastatic or palliative patients.

Entities:  

Keywords:  Chemoradiotherapy; Colorectal cancer; Radiotherapy; Rectal cancer

Year:  2016        PMID: 27493944      PMCID: PMC4945782          DOI: 10.1159/000446486

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  59 in total

1.  Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-05       Impact factor: 3.621

2.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

3.  Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results.

Authors:  Daniel Habermehl; Martin Wagner; Malte Ellerbrock; Markus W Büchler; Oliver Jäkel; Jürgen Debus; Stephanie E Combs
Journal:  Ann Surg Oncol       Date:  2014-11-11       Impact factor: 5.344

4.  Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.

Authors: 
Journal:  Radiology       Date:  2007-02-28       Impact factor: 11.105

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

Review 7.  Reirradiation of locally recurrent rectal cancer: a systematic review.

Authors:  Marianne Grønlie Guren; Christine Undseth; Bernt Louni Rekstad; Morten Brændengen; Svein Dueland; Karen-Lise Garm Spindler; Rob Glynne-Jones; Kjell Magne Tveit
Journal:  Radiother Oncol       Date:  2014-11-26       Impact factor: 6.280

8.  Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients.

Authors:  M G Haddock; L L Gunderson; H Nelson; S S Cha; R M Devine; R R Dozois; B G Wolff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-04-01       Impact factor: 7.038

Review 9.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

Authors:  Laura De Caluwé; Yves Van Nieuwenhove; Wim P Ceelen
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

10.  Neoadjuvant treatment does not influence perioperative outcome in rectal cancer surgery.

Authors:  Alexis Ulrich; Jürgen Weitz; Matthias Slodczyk; Moritz Koch; Dirk Jaeger; Marc Münter; Markus W Büchler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-21       Impact factor: 7.038

View more
  14 in total

1.  Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer.

Authors:  Armin Jarosch; Ulrich Sommer; Andreas Bogner; Christoph Reißfelder; Jürgen Weitz; Mechthild Krause; Gunnar Folprecht; Gustavo B Baretton; Daniela E Aust
Journal:  Oncoimmunology       Date:  2017-11-07       Impact factor: 8.110

2.  Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.

Authors:  Mahnaz Ebrahimpour; Mahshid Mohammadian; Bagher Pourheydar; Zhino Moradi; Zhaleh Behrouzkia
Journal:  J Lasers Med Sci       Date:  2022-02-28

3.  To what extent should the intestinal be resected proximally after radiotherapy: hint from a pathological view.

Authors:  Pei-Huang Wu; Qing-Hua Zhong; Teng-Hui Ma; Qi-Yuan Qin; Xiao-Yan Huang; Ying-Yi Kuang; Huai-Ming Wang; Zi-Xu Yuan; Lei Wang; Dai-Ci Chen
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-10-16

4.  The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.

Authors:  Diana Spiegelberg; Anja Charlotte Lundgren Mortensen; Kartika Dyah Palupi; Patrick Micke; Julin Wong; Borivoj Vojtesek; David Philip Lane; Marika Nestor
Journal:  Front Oncol       Date:  2020-09-11       Impact factor: 6.244

Review 5.  Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.

Authors:  Sadia Islam Kana; Karim Essani
Journal:  Mol Diagn Ther       Date:  2021-03-12       Impact factor: 4.074

6.  RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer.

Authors:  Chao Xiao; Yupeng Wang; Miao Zheng; Jian Chen; Guohe Song; Zhijie Zhou; Chongzhi Zhou; Xing Sun; Lin Zhong; Erxun Ding; Yi Zhang; Liu Yang; Gang Wu; Shifeng Xu; Hong Zhang; Xiaoliang Wang
Journal:  Cancer Sci       Date:  2018-03-10       Impact factor: 6.716

7.  Effects of varying radiation dosages on MMP1 expression, and MMP1 knockdown on the viability and migration of SW620 cells.

Authors:  Fang Ju; Na Li; Wenming Wang; Haicheng Yuan
Journal:  Mol Med Rep       Date:  2019-01-28       Impact factor: 2.952

Review 8.  Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review.

Authors:  Marlon Osorio; Estefanía Martinez; Tonny Naranjo; Cristina Castro
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

9.  An Integrated Analysis of the Response of Colorectal Adenocarcinoma Caco-2 Cells to X-Ray Exposure.

Authors:  Isabella Guardamagna; Leonardo Lonati; Monica Savio; Lucia A Stivala; Andrea Ottolenghi; Giorgio Baiocco
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

10.  In Vitro Anticancer and Radiosensitizing Activities of Phlorethols from the Brown Alga Costaria costata.

Authors:  Olesya S Malyarenko; Tatiana I Imbs; Svetlana P Ermakova
Journal:  Molecules       Date:  2020-07-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.